Citi initiated coverage of Krystal Biotech with a Buy rating and $160 price target. The analyst We expects Krystal’s topical, redosable gene therapy Vyjuvek to gain “rapid adoption” among U.S. patients with dystrophic epidermolysis bullosa. The firm recommends owning the stock for the launch. While the company is currently positioning Vyjuvek as a $750M global market opportunity, this assessment is likely to prove conservative over time as patient identification rates improve with the availability of the first approved DEB therapy, the antilust tells investors in a research note. Citi also anticipates the broader potential of Krystal’s “unique” HSV-1-based gene delivery platform will come into increased focus next year.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on KRYS:
- Krystal Biotech Announces FDA Clearance of Investigational New Drug Application for KB408 for the Treatment of Type 1 Alpha-1 Antitrypsin Deficiency
- Krystal Biotech announces FDA clearance of IND application for KB408
- Krystal Biotech CEO sells $6.36M in common stock
- Krystal Biotech to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
- Krystal Biotech initiated with a Buy at Berenberg